Aberrant activation of FGFR3 signalling has a well-established role in the development of urothelial carcinoma (UC), and occurs as result of activating somatic mutations of FGFR36, overexpression of the wildtype protein7, altered splicing8 and FGFR3 gene fusions9. Here, FGFR3 is linked to urothelial carcinoma.